YU20050410A - Controlled release oxycodone compositions - Google Patents

Controlled release oxycodone compositions

Info

Publication number
YU20050410A
YU20050410A YU20050410A YUP20050410A YU20050410A YU 20050410 A YU20050410 A YU 20050410A YU 20050410 A YU20050410 A YU 20050410A YU P20050410 A YUP20050410 A YU P20050410A YU 20050410 A YU20050410 A YU 20050410A
Authority
YU
Yugoslavia
Prior art keywords
oxycodone
weight
dosage form
hours
controlled release
Prior art date
Application number
YU20050410A
Other languages
Serbo-Croatian (sh)
Inventor
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of YU20050410A publication Critical patent/YU20050410A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invention herewith refers to a controlled release of a solid dosage form for oral administration, that contains an analgetic efficient quantity of oxycodone or oxycodone salts in one matrix, where the speed of the mentioned dosage form has an in vitro dissolution rate when measured by the USP Paddle Method at 100 -1 in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37 °C, between 12.5 % and 42.5 % (by weight) oxycodone salt released after 1 hour, between 25 % and 55 % (by weight) oxycodone salt released after 2 hours, between 45 % and 75 % (by weight) oxycodone salt released after 4 hours and between 55 % and 85 % (by weight) oxycodone salt released after 6 hours, where in vitro dissolution rate is independent of pH, when pH is between 1.6 and 7.2. That dosage form is achieved in the form of a pill. Invention relates to the procedure for preparation of the same oral dosage form.
YU20050410A 1992-11-25 1993-05-21 Controlled release oxycodone compositions YU20050410A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21014692A 1992-11-25 1992-11-25

Publications (1)

Publication Number Publication Date
YU20050410A true YU20050410A (en) 2006-05-25

Family

ID=47559778

Family Applications (3)

Application Number Title Priority Date Filing Date
YU20050409A YU20050409A (en) 1992-11-25 1993-05-21 Controlled release oxycodone compositions
YU20050408A YU20050408A (en) 1992-11-25 1993-05-21 Controlled release oxycodone compositions
YU20050410A YU20050410A (en) 1992-11-25 1993-05-21 Controlled release oxycodone compositions

Family Applications Before (2)

Application Number Title Priority Date Filing Date
YU20050409A YU20050409A (en) 1992-11-25 1993-05-21 Controlled release oxycodone compositions
YU20050408A YU20050408A (en) 1992-11-25 1993-05-21 Controlled release oxycodone compositions

Country Status (2)

Country Link
RS (1) RS50053B (en)
YU (3) YU20050409A (en)

Also Published As

Publication number Publication date
YU20050409A (en) 2006-05-25
YU20050408A (en) 2006-05-25
YU70804A (en) 2005-11-28
RS50053B (en) 2008-11-28

Similar Documents

Publication Publication Date Title
EP0249347A3 (en) Controlled release dihydrocodeine composition
YU35893A (en) CONTROLLED-RELEASE OXIDON FORMULATIONS AND THEIR USE
GB2196848B (en) Controlled release hydromorphone composition
EP0149920A3 (en) Pharmaceutical formulation
RU2005115855A (en) COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION
EP1243269A3 (en) Opioid formulations having extended controlled release
AR042472A1 (en) CONTROLLED RELEASE PREPARATIONS THAT INCLUDE TRAMADOL AND TOPIRAMATO
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
AU3071300A (en) Multiparticulate bisoprolol formulation
YU20050410A (en) Controlled release oxycodone compositions
AU1039400A (en) Opioid analgesic
YU20050413A (en) Controlled release oxycodone compositions